Regeneron Pharmaceuticals Inc. Stock Rises Thursday, Still Underperforms Market

Dow Jones11-22

DJ Regeneron Pharmaceuticals Inc. Stock Rises Thursday, Still Underperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Regeneron Pharmaceuticals Inc. $(REGN)$ inched 0.15% higher to $744.50 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.53% to 5,948.71 and the Dow Jones Industrial Average rising 1.06% to 43,870.35.

The stock's rise snapped a two-day losing streak.

Regeneron Pharmaceuticals Inc. closed $466.70 below its 52-week high ($1,211.20), which the company achieved on August 27th.

The stock underperformed when compared to some of its competitors Thursday, as Amgen Inc. $(AMGN)$ rose 0.71% to $289.90, Moderna Inc. $(MRNA)$ rose 3.55% to $38.25, and Gilead Sciences Inc. $(GILD)$ rose 1.27% to $89.76.

Trading volume (971,896) eclipsed its 50-day average volume of 769,998.

Data source: Dow Jones Market Data, FactSet. Data compiled November 21, 2024.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

November 21, 2024 16:46 ET (21:46 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment